Product menu

SHINGRIX: Coverage information

SHINGRIX: Private coverage & public funding information

Ontario publicly funded shingles (herpes zoster) program1,2

Updated: October 2020.

Overview: SHINGRIX is covered on the Ontario publicly funded shingles immunization program for Ontario seniors age 65 to 73 years.  For complete eligibility criteria, click the button below.

Access: Eligible individuals are able to receive SHINGRIX through their primary healthcare provider.

Learn more

Veteran Affairs Canada (VAC)3

Updated: January 2021.

Overview: SHINGRIX is covered on the Veteran Affairs Canada Federal Plan for all members 50 years of age and older.

Access: Eligible members require a prescription from their health professional authorized to prescribe pharmaceuticals.

Learn more

First Nations Health Authority (FNHA)4

Updated: February 2021.

Overview: SHINGRIX is covered on the First Nations Health Authority Program for First Nations Elders who are 65 years old and older.

Access: The SHINGRIX vaccine can be prescribed by a physician or nurse practitioner, or obtained directly from the pharmacist.

Learn more

Non-Insured Health Benefits (NIHB) program5

Updated: January 2021.

Overview: SHINGRIX is covered on the Non-Insured Health Benefits program for clients between 65 and 70 years of age. 

Access: A prescription from a licensed practitioner is required for SHINGRIX to be processed as a benefit.

Learn more

Private insurance

The cost of SHINGRIX may be covered by your patient’s private insurance. They can contact their insurance provider and give the DIN (drug identification number) below to find out.

SHINGRIX DIN: 02468425.

Virus icon

What was shown to be the dominant driver of shingles?

Learn about age-related decline in immunity.6

Learn more
Patient icon

Meet the patients that are eligible to receive SHINGRIX

Nearly everyone ≥50 years old should be protected against shingles.7

Learn more
Vaccine icon

Dosing and administration

Discover more about administering the vaccine and discussing shingles and vaccination with your patients.

Learn more

References

  1. Ontario Ministry of Health. Transition to Publicly Funded Shingrix Vaccine for Ontario’s Shingles (Herpes Zoster) Immunization Program: Information for Health Care Providers. Available at: https://www.health.gov.on.ca/en/pro/programs/immunization/docs/shingles_hcp_qa_en.pdf. 
  2. Ontario Ministry of Health. Guidance for Routine Immunization Services During COVID-19. Available at: https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/Immunization_Services_during_COVID-19_08-26-2020.pdf.
  3. Veteran Affairs Canada. Details: Drug 02468425: SHINGRIX suspension 50mcg/0.5mL. Available at: https://www.veterans.gc.ca/eng/financial-support/medical-costs/treatment-benefits/poc10/search/form_detail/02468425. 
  4. First Nations Health Authority. First Nations Health Authority Expanding Elders Coverage of Shingrix Shingles Vaccine. January 29, 2021. Available at: https://www.fnha.ca/benefits/health-benefits-news/first-nations-health-authority-expanding-elders-coverage-of-shingrix-shingles-vaccine. 
  5. Indigenous Services Canada. Non-Insured Health Benefits (NIHB) Program: New Product Listing - Shingrix. January 11, 2021. Available at: https://nihb.express-scripts.ca/NIHBProvider/benefits/pharmacy?page=pharmacy-bulletins&benefit=pharmacy.
  6. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1-30.
  7. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.

Trademarks are owned by or licensed to the GSK group of companies.

©2021 GSK Group of Companies or its licensor.

PM-CA-SGX-WCNT-210001 | November 2021